Context Therapeutics Inc. (CNTX)
| Market Cap | 230.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -36.12M |
| Shares Out | 91.88M |
| EPS (ttm) | -0.38 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 973,993 |
| Open | 2.350 |
| Previous Close | 2.340 |
| Day's Range | 2.320 - 2.535 |
| 52-Week Range | 0.490 - 3.620 |
| Beta | 1.83 |
| Analysts | Strong Buy |
| Price Target | 6.60 (+162.95%) |
| Earnings Date | May 8, 2026 |
About CNTX
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Penn... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for CNTX stock is "Strong Buy." The 12-month stock price target is $6.6, which is an increase of 162.95% from the latest price.
News
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer
Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02, 2026...
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalent...
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bis...
Context Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The discussion highlighted a robust pipeline of T-cell engagers targeting claudin 6, mesothelin, and nectin-4, with a focus on overcoming ADC resistance in solid tumors. Key data readouts are expected this year, with strategic moves toward less frequent dosing, outpatient administration, and combination therapies.
Context Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Three T-cell engager programs are advancing in solid tumors, with Claudin 6 phase I data due Q2 and mesothelin data mid-2026. Innovations in antibody engineering aim to improve safety and efficacy, while strong financing supports ongoing clinical milestones.
Context Therapeutics to Participate in Upcoming Investor Conferences
PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The pipeline centers on T-cell engagers for solid tumors, with Claudin-6 and Mesothelin in clinical trials and Nectin-4 approaching clinical entry. Early data show promising efficacy and safety, with rapid development and broad patient inclusion as key goals.
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bisp...
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equiva...
Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer
Saint-Genis-Pouilly, France, 28 October 2025 – Step Pharma (“the Company”), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Karen L. Smith, MD, ...
Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting
PHILADELPHIA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bisp...
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PHILADELPHIA, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific a...
Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations ...
Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting
Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutic...
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibo...
Context Therapeutics Reports First Quarter 2025 Operating and Financial Results
CTIM-76 and CT-95 in Phase 1 Clinical Trials Cash and cash equivalents of $89.4 million as of March 31, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PH...
Context Therapeutics Announces Chief Medical Officer Transition
Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer Board Member Dr. Karen Smith to serve as Interim Chief Medical Officer
Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting
Preclinical data demonstrates unique binding location of CT-95 on mesothelin and avoidance of binding to shed mesothelin Data supports ongoing Phase 1 clinical trial for CT-95 PHILADELPHIA, April 3...
Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context's second T cell engaging bispecific antibody to enter the clinic in 2025 PHILADELPHIA, April 09, 2025 (GLOBE NEWSWIRE) ...
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025
PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bis...
Context Therapeutics Reports Full Year 2024 Operating and Financial Results
CTIM-76 first patient dosed in January 2025 Cash and cash equivalents of $94.4 million as of December 31, 2024 Company expects its cash and cash equivalents will continue to fund operations into 2027 ...
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap...
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experience Transition further highlights transformation of the Board to lead Context into next phase of growth PHILADELPHIA, Jan. 13, 2...
Context Therapeutics Transcript: Stifel 2024 Healthcare Conference
The presentation detailed a pipeline of T-cell engaging bispecific antibodies for solid tumors, emphasizing high affinity CD3, logic gating, and a roll-up asset acquisition strategy. Recent clinical and industry advances support renewed interest and combination strategies with ADCs.